2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy
2017
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.Peer-Reviewed Original ResearchConceptsMF/SSOverall survivalSézary syndromeHazard ratioImproved survivalMycosis fungoidesPatient survivalHighest quintileLowest quintileTreatment volumeImproved overall survivalMultivariable Cox regressionNational Cancer DatabaseKaplan-Meier methodAnnual patient volumeNational database analysisLog-rank testContinuous variablesMedian followMultivariable analysisCox regressionOS survivalCancer DatabasePatientsPatient volume
2016
Adjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factorsThe effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas
Stahl JM, Corso CD, Park HS, An Y, Rutter CE, Han D, Roberts KB. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas. European Journal Of Surgical Oncology 2016, 43: 168-174. PMID: 27335080, DOI: 10.1016/j.ejso.2016.05.031.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasOverall survivalR1 resectionR0 resectionMargin statusNational Cancer Data BaseRetroperitoneal soft tissue sarcomaCox proportional hazards regressionPropensity scoreMultivariable logistic regression modelMedian overall survivalMicroscopic margin statusPre-operative RTReceipt of RTUnderwent R0 resectionSuperior overall survivalSmaller tumor sizeLow tumor gradeProportional hazards regressionLog-rank testRetroperitoneal soft tissueLogistic regression modelsLiposarcoma histologyR1 patientsRadiotherapy receipt
2015
Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma
Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal Of The American Academy Of Dermatology 2015, 72: 1010-1015.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllograftsAutograftsBiopsy, NeedleFemaleFollow-Up StudiesGraft RejectionGraft SurvivalHematopoietic Stem Cell TransplantationHumansImmunohistochemistryLymphoma, T-CellLymphoma, T-Cell, CutaneousMaleMiddle AgedPanniculitisPositron-Emission TomographyRetrospective StudiesRisk AssessmentSampling StudiesSkin NeoplasmsTreatment OutcomeConceptsHematopoietic stem cell transplantationT-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaAllogeneic hematopoietic stem cell transplantationPanniculitis-like T-cell lymphomaCutaneous T-cell lymphomaStem cell transplantationPCGD-TCLCell transplantationPrimary cutaneous γδ T-cell lymphomaCutaneous γδ T-cell lymphomaAutologous hematopoietic stem cell transplantationOutcome of HSCTAdvanced-stage mycosis fungoidesΓδ T-cell lymphomaPanniculitic T-cell lymphomaAggressive T-cell lymphomaMatched-related donorsMatched-unrelated donorsT-cell infiltratesPromising treatment modalityAggressive therapyMost patientsMycosis fungoidesInferior outcomes
2012
Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2011
Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis
Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 2011, 118: 4212-4219. PMID: 22213196, DOI: 10.1002/cncr.27373.Peer-Reviewed Original ResearchConceptsAtypical teratoid rhabdoid tumorMedian overall survivalOverall survivalRT useLandmark analysisRhabdoid tumorRare central nervous system malignanciesNational Cancer Institute's SurveillanceCentral nervous system malignanciesCox proportional hazards modelRole of radiotherapyEnd Results (SEER) databaseEnd Results analysisSignificant survival benefitProspective clinical trialsGross total resectionPatients ages 4Nervous system malignanciesImmortal time biasProportional hazards modelLong-term survivorshipAdjuvant radiotherapyInitial radiotherapyPrimary endpointInitial management
2007
Size matters: gastric pouch size correlates with weight loss after laparoscopic Roux-en-Y gastric bypass
Roberts K, Duffy A, Kaufman J, Burrell M, Dziura J, Bell R. Size matters: gastric pouch size correlates with weight loss after laparoscopic Roux-en-Y gastric bypass. Surgical Endoscopy 2007, 21: 1397-1402. PMID: 17332953, DOI: 10.1007/s00464-007-9232-x.Peer-Reviewed Original ResearchConceptsLaparoscopic Roux-en-Y gastric bypassPreoperative body mass indexExcess weight lossBody mass indexGastric pouch sizeRoux-en-Y gastric bypassPouch sizeGastric bypassWeight lossIncreased preoperative BMIMale genderSuccess of surgical therapyMean pouch sizePostoperative day 1ResultsThe mean ageYale-New Haven HospitalUpper gastrointestinal seriesProspective databaseSurgical therapyMorbid obesityStudy patientsBariatric surgeryNew Haven HospitalMean ageMass index
2004
Relation of clinical success in coronary brachytherapy to dose
Singh HS, Yue N, Azimi N, Nath R, Roberts KB, Pfau S. Relation of clinical success in coronary brachytherapy to dose. The American Journal Of Cardiology 2004, 94: 847-852. PMID: 15464663, DOI: 10.1016/j.amjcard.2004.06.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCase-Control StudiesConnecticutCoronary AngiographyCoronary RestenosisCoronary VesselsDose-Response Relationship, RadiationFemaleFollow-Up StudiesHumansMaleMiddle AgedMultivariate AnalysisRadiotherapy DosageRetrospective StudiesStatistics as TopicTreatment OutcomeUltrasonography, InterventionalConceptsTreatment failureExternal elastic membraneTreatment successStent restenosisIntravascular ultrasoundAdequate dose deliveryRecurrent restenosisLesion patternsPrimary treatmentCoronary brachytherapyClinical successPatientsDose prescriptionRadiation delivery systemsArteryRestenosisGyDoseBrachytherapyDose thresholdRadiation delivery devicePotential causesDose deliveryIntravascular brachytherapyTreatment
2003
Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices
Singh HS, Roberts KB, Yue N, Nath R, Song GH, Azimi N, Pfau S. Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices. Cardiovascular Revascularization Medicine 2003, 4: 126-132. PMID: 14984712, DOI: 10.1016/s1522-1865(03)00183-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBlood Vessel Prosthesis ImplantationBrachytherapyConnecticutCoronary AngiographyCoronary Artery BypassCoronary RestenosisCoronary StenosisEquipment DesignFamily PracticeFemaleFollow-Up StudiesHospital MortalityHumansMaleMiddle AgedRadiation DosageReoperationRetrospective StudiesStentsTreatment OutcomeConceptsMajor adverse cardiac eventsStent restenosisAverage treatment ageEffectiveness of brachytherapyAdverse cardiac eventsSingle institution experienceMinimal lumen diameterRandomized clinical trialsLesion-specific characteristicsSpectrum of patientsMACE rateHospital deathCardiac eventsRenal failureUnstable anginaClinical outcomesCoronary lesionsTreatment failureInstitution experienceFrequent presentationInterventional therapyClinical trialsGeneral populationInterventional practicePatients
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalitiesInterim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix
Roberts K, Urdaneta N, Vera R, Vera A, Gutierrez E, Aguilar Y, Ott S, Medina I, Sempere P, Rockwell S, Sartorelli A, Fischer D, Fischer J. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix. International Journal Of Cancer 2000, 90: 206-223. PMID: 10993961, DOI: 10.1002/1097-0215(20000820)90:4<206::aid-ijc4>3.0.co;2-o.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaDisease-free survivalMitomycin CSurvival rateRadical radiotherapyCervix cancerActuarial disease-free survival rateLocal recurrence-free survival rateActuarial disease-free survivalAdvanced squamous cell carcinomaOpen phase III trialDisease-free survival ratesRecurrence-free survival ratesDistant recurrence-free survivalAcute radiation reactionsIII-IVA patientsIntravenous mitomycin CMild hematologic toxicityNon-hematologic toxicitiesTreatment-related deathsActuarial survival rateAdvanced stage diseasePhase III trialsMitomycin C groupRecurrence-free survival
1999
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia
Jillella A, Doria R, Khan K, Zelterman D, Ahmad Y, Smith B, Holmes W, Becker P, Roberts K, Rappeport J. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation 1999, 23: 1095-1100. PMID: 10382947, DOI: 10.1038/sj.bmt.1701786.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationTotal body irradiationBone marrow transplantationConditioning regimenMarrow transplantationMyeloablative regimenRelapse rateBody irradiationHematologic malignanciesAntileukemic effectGood prognosis diseaseHigh-dose cytosineHost disease (GVHD) prophylaxisShort-course methotrexateEvidence of diseaseOverall relapse rateHigh-dose AraPoor prognosis diseaseKaplan-Meier estimatesActuarial survivalConditioning regimensDisease prophylaxisMyeloablative regimensProspective studyRegimen
1998
Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy
Turner B, Knisely J, Kacinski B, Haffty B, Gumbs A, Roberts K, Frank A, Peschel R, Rutherford T, Edraki B, Kohorn E, Chambers S, Schwartz P, Wilson L. Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 77-84. PMID: 9422561, DOI: 10.1016/s0360-3016(97)00581-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyChemotherapy, AdjuvantCystadenocarcinoma, PapillaryDisease-Free SurvivalFemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesSalvage TherapyUterine NeoplasmsConceptsUterine papillary serous carcinomaWhole pelvic radiation therapyWhole-abdomen radiation therapyComplete surgical stagingDisease-free survivalActuarial disease-free survivalFIGO stage IPapillary serous carcinomaSurgical stagingActuarial OSOverall survivalSalvage rateStage IRadiation therapyUPSC patientsVaginal brachytherapyMyometrial invasionSerous carcinomaLDR brachytherapyRadiation Therapy Oncology Group (RTOG) grade 1DFS of patientsPara-aortic lymph node samplingConventional external beam radiotherapyFIGO stage IARTOG grade 3
1996
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissionsRadiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium
Fishman D, Roberts K, Chambers J, Kohorn E, Schwartz P, Chambers S. Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium. Gynecologic Oncology 1996, 61: 189-196. PMID: 8626131, DOI: 10.1006/gyno.1996.0123.Peer-Reviewed Original ResearchConceptsClinical stage IOperable patientsInoperable patientsIntercurrent diseaseStage IRadiation therapyMedian survivalEndometrioid carcinomaMore deathsMedian disease-free intervalExclusive radiation therapyMedically Inoperable PatientsStage I groupCancer-specific survivalDisease-free intervalStage II diseaseOverall survival rateShorter overall survivalOperable diseaseOperable groupEndometrial cancerOverall survivalSuch patientsShorter survivalClinical stage
1995
Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E, Doria R, Farber L, Roberts K, Cooper D. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. The Cancer Journal 1995, 1: 267-73. PMID: 9166487.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMechlorethamineMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrednisoneProcarbazineRemission InductionSalvage TherapyTime FactorsTreatment OutcomeVinblastineVincristineConceptsFailure-free survivalStage IV diseaseAdvanced Hodgkin's diseaseDisease-free survivalHodgkin's diseaseComplete remissionSecond malignanciesRadiation therapyLong-term disease-free survivalInvolved-field radiation therapyDurable second remissionsMOPP/ABVDRecurrent Hodgkin's diseaseInitial complete remissionCombined modality therapyMonths of chemotherapyLong-term resultsResults of treatmentSalvage therapySecond remissionInitial remissionUntreated patientsModality therapyOverall survivalChemotherapy program